Home › Research › Treatments
Treating Alzheimer Disease With Antiamyloid Therapies—The Real-World Experience Grows
Rita Rubin. JAMA, 2025-08-22
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
This Medical News article discusses the safety and effectiveness of lecanemab and donanemab in treating mild cognitive impairment and early Alzheimer disease outside clinical trials.
What this study adds
Evidence grade: Low
This news article discusses the safety and effectiveness of lecanemab and donanemab for mild cognitive impairment and early Alzheimer disease outside clinical trials. It reports on the growing real-world experience rather than presenting new trial data.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rubin, R. (2025). Treating Alzheimer Disease With Antiamyloid Therapies—The Real-World Experience Grows. JAMA. https://doi.org/10.1001/jama.2025.14180
Vancouver
Rubin R. Treating Alzheimer Disease With Antiamyloid Therapies—The Real-World Experience Grows. JAMA. 2025. doi:10.1001/jama.2025.14180. PMID: 40844810.
BibTeX
@article{rubin2025-40844810,
author = {Rubin, Rita},
title = {{Treating Alzheimer Disease With Antiamyloid Therapies—The Real-World Experience Grows}},
journal = {JAMA},
year = {2025},
doi = {10.1001/jama.2025.14180},
pmid = {40844810},
url = {https://doi.org/10.1001/jama.2025.14180}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- This Medical News article discusses the safety and effectiveness of lecanemab and donanemab in treating mild cognitive impairment and early Alzheimer disease outside clinical trials.
Why it matters
This news article discusses the safety and effectiveness of lecanemab and donanemab for mild cognitive impairment and early Alzheimer disease outside clinical trials. It reports on the growing real-world experience rather than presenting new trial data.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 40 of the 97 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (JAMA) |
| Journal's citation record | 4 / 4 | JAMA: journal h-index 1,011 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Rita Rubin: h-index 9 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40844810) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 40 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 40 of the 97 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.